Navigation Links
Arthritis: What Wnt wrong?

The cellular signaling protein Wnt, which is involved in embryonic development and cancer, contributes to disease progression of both rheumatoid arthritis and osteoarthritis. The article by Nakamura et al., "Expression profiles and functional analyses of Wnt-related genes in human joint disorders," appears in the July issue of The American Journal of Pathology and is accompanied by a commentary.

Wnt is best known as a proto-oncogene because its disruption can lead to cancer in various organs such as colon, lung, and breast. However, mounting evidence also points to its involvement in arthritic joint disease. Comprehensive analysis of the entire Wnt gene family in the progression of arthritis has been lacking until now.

Researchers at Shinshu University School of Medicine in Nagano, Japan, examined 19 members of the Wnt gene family to determine exactly which of these genes were involved in arthritic joint disease. This extensive study, performed under the direction of Dr. Shigeyuki Wakitani, who is an assistant professor at the Department of Orthopedic Surgery, Shinshu University School of Medicine, examined joint tissue from patients who underwent total knee replacement for rheumatoid arthritis (RA), osteoarthritis (OA), or non-arthritic injury.

Using several molecular methods, Wakitani's group identified Wnt-7b and -10a as genes that were significantly upregulated in the arthritic knee tissues. However, protein expression studies revealed that only Wnt-7b was produced in arthritic joints, with strong protein localization to the synovium (or joint lining) and weak localization to cartilage and bone. In addition, strong Wnt-7b expression most frequently correlated with areas of high inflammation.

The authors also examined whether inflammatory cytokines were produced in primary cartilage and synovial cells from arthritic versus normal joints. While OA cells did not differ from controls, primary RA cells produced TNF-a, IL-1ß and IL-6 at levels 2- to 4-fold above controls. Importantly, this effect could be replicated in normal cells when they were engineered to express Wnt-7b, demonstrating the importance of Wnt-7b in the inflammatory response of RA.

The above findings identify a role for Wnt-7b in arthritic processes. Arthritic diseases manifest differently depending on the type, with RA exhibiting inflammation of the synovium and loss of cartilage and bone and OA exhibiting narrowing of joint space, loss of protective cartilage, and growth of bone cysts (or osteophytes).

Interestingly, Wnt-7b was strongly upregulated within joints at sites of disease manifestation: mainly in synovium of RA but in synovium, cartilage, osteophyte, and bone of OA. In addition, the findings that Wnt-7b was frequently found at sites of inflammation and elicited an inflammatory response are consistent with inflammation as a hallmark of RA disease.

Co-author Dr. Yukio Nakamura is an Orthopedic Surgeon at Shinshu University School of Medicine and is currently at Howard Hughes Medical Institute/Case Western Reserve University as a research associate. Nakamura has been studying the biological activities and signaling pathway of a Wnt-related gene that causes severe joint degenerative disease in humans.

"More specific analyses such as gain-of-function and loss-of-function study of Wnt-7b will give us a clue which Wnt-7b would be an important pathobiological factor in rheumatoid arthritis," added Nakamura. Future studies will investigate the role of Wnt and its signaling partners in arthritic joint destruction. Further delineation of the Wnt signaling pathway in arthritic progression may provide future therapies for the growing number of arthritis suffers.

According to The National Center for Health Statistics, over 42 million US adults, or 20% of the population, complained of arthritic symptoms in 2002.


'"/>

Source:American Journal of Pathology


Related biology news :

1. New comparative toxicogenomics database
2. Measuring the impact of post-genomics on Mediterranean populations
3. Owl genomics presents a HEPATOCHIP for diagnosis of non-alcoholic steatohepatitis
4. Drawing with DNA: Bioart illuminates genomics
5. Study reveals genomics of inflammation from severe injury
6. NIH launches comprehensive effort to explore cancer genomics
7. Environmental metagenomics diagnosing extreme environments, tapping opportunities for clean energy
8. Ticks, flukes, and genomics: Emerging pathogens revealed
9. UC San Diego partners with Venter Institute to build marine microbial genomics cyberinfrastructure
10. Advanced genomics and proteomics improve the diagnosis and treatment of a deadly lung disease
11. Large-scale genomics project will hunt genes behind common childhood diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 23, 2016 , ... Supplyframe, the Industry Network for electronics ... Lab . Located in Pasadena, Calif., the Design Lab’s mission is to bring ... designed, built and brought to market. , The Design Lab is Supplyframe’s physical ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published ... how a patient who developed lymphedema after being treated for breast cancer benefitted from ... the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
Breaking Biology Technology: